Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Am J Surg Pathol. 2013 Jun;37(6):853–859. doi: 10.1097/PAS.0b013e31827fcc18

Figure 1.

Figure 1

Recurrence-free survival analysis stratified by the (A) WHO 2004 and (B) WHO 2010 classification schemes. (A) Patients with WD endocrine carcinoma (WDCA) showed significantly inferior RFS than patients with WD endocrine tumor with benign behavior (BB) or uncertain behavior (UB; p =0.0057). (B) Using the WHO 2010 classification, grade 3 tumors (neuroendocrine carcinoma) had significantly shortened RFS than grade 1 or 2 PanNETs (p<0.0001).